Monitor initiation of the Phase 3 study in H2 2026 and any subsequent data readouts as the primary catalysts. The brand name approval alone is not a price-moving event for a $9M market cap pre-revenue biotech.
Price Chart
Executive Summary
Quoin Pharmaceuticals announced FDA conditional approval of QYLEKI as the proposed brand name for QRX003, its investigational treatment for Netherton Syndrome. The company expects to initiate a pivotal Phase 3 study in H2 2026 with a potential NDA filing in 2027. This is a routine regulatory milestone for a pre-revenue clinical-stage biotech with no approved products and a $9M market cap.
Key Facts
- FDA conditionally approved QYLEKI as the proposed brand name for QRX003 for Netherton Syndrome
- Pivotal Phase 3 study expected to initiate in H2 2026
- Potential NDA filing anticipated in 2027
- QRX003 holds Orphan Drug Designation in US, EU, and Japan, plus Fast Track and Rare Pediatric Disease Designations from FDA
- No currently approved treatment for Netherton Syndrome
Financial Impact
No financial figures disclosed; company is pre-revenue with $9M market cap
Risk Factors
- Clinical trial failure risk remains the primary downside
- Regulatory approval not guaranteed even with orphan designations
- Cash runway and potential dilution risk not addressed in this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-076822 |
| Document: tm2618505d1_ex99-1.htm | 0001104659-26-076822 |
| Document: 0001104659-26-076822-index-headers.html | 0001104659-26-076822 |
| Document: 0001104659-26-076822-index.html | 0001104659-26-076822 |
| Document: 0001104659-26-076822.txt | 0001104659-26-076822 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 12, 2026 6d ago | ANALYST-UPGRADE | $4.36 $4.15 | ▼ −4.82% | ▼ −4.80% | $3.90 (−10.55%) |
Sep 2, 2026 6w ago | Insider Cluster | $6.74 $7.87 | ▲ +16.77% | ▲ +15.72% | $3.90 (−42.14%) |
Aug 28, 2026 7w ago | 8-K | $6.12 $6.22 | ▲ +1.63% | ▲ +1.93% | $3.90 (−36.27%) |
Aug 28, 2026 7w ago | Press Release | $6.12 $6.22 | ▼ −1.63% | ▼ −1.93% | $3.90 (+36.27%) |
Aug 28, 2026 7w ago | Press Release | $6.12 $6.22 | ▲ +1.63% | ▲ +1.93% | $3.90 (−36.27%) |
Aug 20, 2026 8w ago | 8-K | $5.57 $5.42 | ▼ −2.69% | ▼ −2.40% | $3.90 (−29.98%) |
Aug 7, 2026 10w ago | Press Release | $4.79 $5.36 | ▲ +11.90% | ▲ +11.93% | $3.90 (−18.58%) |
Jun 23, 2026 16w ago | 8-K | $3.83 $4.20 | ▲ +9.66% | ▲ +9.52% | $3.90 (+1.83%) |
May 7, 2026 23w ago | Press Release | $6.37 $5.93 | ▼ −6.91% | ▼ −7.74% | $3.90 (−38.78%) |
May 5, 2026 23w ago | ANALYST-UPGRADE | $6.31 $6.43 | ▲ +1.90% | ▲ +0.52% | $3.90 (−38.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access